ImmunityBio is a clinical-stage immunotherapy company developing immunotherapy and cell therapy platforms to activate innate and adaptive immune responses against cancer and infectious pathogens. Its lead product, N-803 (Anktiva), is being developed in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without Ta or T1 disease. The company resubmitted a Biologics License Application (BLA) on October 23, 2023, and the FDA set a PDUFA goal date of April 23, 2024 for the resubmission. Proceeds from the recent financing are intended to accelerate commercialization in anticipation of potential FDA approval, expand development across urological cancers and other solid tumors, and fund ongoing operations and clinical trials to expand Anktiva indications. Financially, ImmunityBio received $210 million of gross proceeds at closing from a combined royalty financing and equity investment by Oberland Capital, with additional contingent funding tied to regulatory approval and an equity purchase option. The company also amended debt arrangements with Nant Capital—extending maturities on promissory notes of approximately $505 million and agreeing to potential conversions of up to $380 million of principal plus accrued interest—concurrent with the financing. NantCell is building an integrated immunotherapy platform aimed at a chemotherapy‑free cancer vaccine, combining adenovirus and yeast delivery systems, bispecific/trispecific fusion cytokine proteins, mRNA, monoclonal antibodies and targeted NK/T cell therapies. Its lead asset is an IL15/Fc bispecific fusion protein that has entered registration trials (including two bladder cancer trials) and received Fast Track designation for relapsed non‑muscle invasive bladder cancer. The company reports active enrollment in registration trials across 15 indications and a clinical portfolio that includes seven molecules in Phase 1, four in Phase 2, and three in registration trials; 14 unique biomolecules have been tested in over 1,000 patients. The preclinical pipeline includes 28 unique molecules (fusion proteins, mRNA, cytokines and antibodies), six of which were described as IND‑ready with anticipated filings in 2019. NantCell has developed GMP manufacturing capabilities for its lead cytokine, delivery systems, and an automated “GMP in a Box” for targeted NK and T cell production. Financially, Celgene completed a crossover funding round in December 2018 and has been a strategic investor in the company.

Total raised

$340M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2024